These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29605513)

  • 1. Pharmacovigilance in Crisis: Drug Safety at a Crossroads.
    Price J
    Clin Ther; 2018 May; 40(5):790-797. PubMed ID: 29605513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance: An Overview.
    Beninger P
    Clin Ther; 2018 Dec; 40(12):1991-2004. PubMed ID: 30126707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities.
    Lewis DJ; McCallum JF
    Ther Innov Regul Sci; 2020 Jul; 54(4):888-899. PubMed ID: 32557311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
    Pariente A; Micallef J; Lahouegue A; Molimard M; Auffret M; Chouchana L; Denis B; Faillie JL; Grandvuillemin A; Letinier L; Pierron E; Pons C; Pujade I; Rubino H; Salvo F
    Therapie; 2023; 78(1):131-143. PubMed ID: 36572627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance strategy: opportunities for cross-national learning.
    Fermont I
    Isr J Health Policy Res; 2019 Jun; 8(1):54. PubMed ID: 31217025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial Intelligence and the Future of the Drug Safety Professional.
    Danysz K; Cicirello S; Mingle E; Assuncao B; Tetarenko N; Mockute R; Abatemarco D; Widdowson M; Desai S
    Drug Saf; 2019 Apr; 42(4):491-497. PubMed ID: 30343417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European pharmacovigilance: increasingly outsourced to drug companies.
    Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategic Partnerships in Pharmacovigilance: Business, Legal, and Regulatory Domains.
    Youssef A; Blanchard NL; Hammad TA
    Clin Ther; 2024 May; 46(5):424-428. PubMed ID: 38677979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance.
    Kassekert R; Grabowski N; Lorenz D; Schaffer C; Kempf D; Roy P; Kjoersvik O; Saldana G; ElShal S
    Drug Saf; 2022 May; 45(5):439-448. PubMed ID: 35579809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations.
    Peters T; Soanes N; Abbas M; Ahmad J; Delumeau JC; Herrero-Martinez E; Paramananda M; Piper J; Smail-Aoudia F; van der Spuij W; Veizovic T; Winstanley G;
    Drug Saf; 2021 Jan; 44(1):17-28. PubMed ID: 33289904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.
    Mockute R; Desai S; Perera S; Assuncao B; Danysz K; Tetarenko N; Gaddam D; Abatemarco D; Widdowson M; Beauchamp S; Cicirello S; Mingle E
    Pharmaceut Med; 2019 Apr; 33(2):109-120. PubMed ID: 31933254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will the future of pharmacovigilance be more automated?
    Salvo F; Micallef J; Lahouegue A; Chouchana L; Létinier L; Faillie JL; Pariente A
    Expert Opin Drug Saf; 2023; 22(7):541-548. PubMed ID: 37435796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role and Responsibilities of Various Stakeholders in Pharmacovigilance (PV).
    Phougat P; Beniwal M; Kapoor G; Aggarwal N; Kumari A; Sharma R; Chopra H; Sharma R; Kamal MA
    Curr Drug Saf; 2024 Feb; ():. PubMed ID: 38318830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in resource-limited countries.
    Olsson S; Pal SN; Dodoo A
    Expert Rev Clin Pharmacol; 2015; 8(4):449-60. PubMed ID: 26041035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy.
    Adams C; Keller M; Michlitsch JG; Aguayo-Hiraldo P; Chen K; Hossain MZ; Davis A; Park JR; Verneris MR; Gardner RA
    Transplant Cell Ther; 2024 May; 30(5):475-487. PubMed ID: 38447751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why Are We Still Creating Individual Case Safety Reports?
    Streefland MB
    Clin Ther; 2018 Dec; 40(12):1973-1980. PubMed ID: 30420290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices.
    Huysentruyt K; Kjoersvik O; Dobracki P; Savage E; Mishalov E; Cherry M; Leonard E; Taylor R; Patel B; Abatemarco D
    Drug Saf; 2021 Mar; 44(3):261-272. PubMed ID: 33523400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.